Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
出版年份 2021 全文链接
标题
Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
作者
关键词
-
出版物
Circulation-Cardiovascular Quality and Outcomes
Volume 14, Issue 12, Pages -
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2021-12-22
DOI
10.1161/circoutcomes.121.007971
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in patients with Atrial Fibrillation and Atrial Flutter
- (2021) Hasan Ashraf et al. AMERICAN JOURNAL OF MEDICINE
- Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation
- (2021) So-Ryoung Lee et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Effect of non‐recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta‐analysis
- (2021) Xuyang Liu et al. CLINICAL CARDIOLOGY
- Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
- (2021) Jan Steffel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation
- (2021) I-Chih Chen et al. MEDICINE
- Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
- (2020) Alexandros Briasoulis et al. BMC Cardiovascular Disorders
- Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan
- (2020) Tatsuya Maruhashi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Off-label dosing of non–vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation
- (2020) Yi-Hsin Chan et al. HEART RHYTHM
- Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants
- (2020) Alan John Camm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence
- (2020) Mario Bo et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function
- (2019) So-Ryoung Lee et al. STROKE
- Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry
- (2019) Nobuhiro Murata et al. CIRCULATION JOURNAL
- Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation
- (2019) Ronen Arbel et al. AMERICAN JOURNAL OF MEDICINE
- Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation
- (2019) Wen-Han Cheng et al. STROKE
- Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
- (2019) Takanori Ikeda et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Impact of direct oral anticoagulants off‐label doses on clinical outcomes of atrial fibrillation patients: a systematic review
- (2019) Joana Santos et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
- (2018) Jan Steffel et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
- (2018) Yi‐Hsin Chan et al. Journal of the American Heart Association
- Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation
- (2018) Yi-Cheng Lin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
- (2018) Tze-Fan Chao et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials
- (2018) Kang-Ling Wang et al. EUROPEAN HEART JOURNAL
- Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
- (2017) Xiaoxi Yao et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Standard dose versus low dose non–vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials
- (2016) Kang-Ling Wang et al. HEART RHYTHM
- Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes
- (2016) Benjamin A. Steinberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method
- (2014) Joanna IntHout et al. BMC Medical Research Methodology
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation